Citations

Clear

7552 citation(s) found for "Ho, Matthew".

Initial elevations in glutamate and dopamine neurotransmission decline with age, as does exploratory behavior, in LRRK2 G2019S knock-in mice
Volta, Mattia , Beccano-Kelly, Dayne , Paschall, Sarah A. , Cataldi, Stefano , MacIsaac, Sarah E, Kuhlmann, Naila , Kadgien, Chelsie , Tatarnikov, Igor , Fox, Jesse D. , Khinda, Jaskaran, Mitchell, Emma , Bergeron, Sabrina , Melrose, Heather L. , Farrer, Matthew J. , Milnerwood, Austen J. , Beccano-Kelly, Dayne A , Melrose, Heather

Mayo Clinic

eLife | September 20, 2017 | Volume: 6 | Issue: No issue available | Pages: No page available

10.7554/elife.28377 | PMID 28930069 Get It

LRRK2 mutations produce end-stage Parkinson’s disease (PD) with reduced nigrostriatal dopamine, whereas, asymptomatic carriers have increased dopamine turnover and altered brain connectivity. LRRK2 pathophysiology remains unclear, but reduced dopamine and mitochondrial abnormalities occur in aged G2019S mutant knock-in (GKI) mice. Conversely, cultured GKI neurons exhibit increased synaptic transmission. We assessed behavior and synaptic glutamate and dopamine function across a range of ages. Young GKI mice exhibit more vertical exploration, elevated glutamate and dopamine transmission, and aberrant D2-receptor responses. These phenomena decline with age, but are stable in littermates. In young GKI mice, dopamine transients are slower, independent of dopamine transporter (DAT), increasing the lifetime of extracellular dopamine. Slowing of dopamine transients is observed with age in littermates, suggesting premature ageing of dopamine synapses in GKI mice. Thus, GKI mice exhibit early, but declining, synaptic and behavioral phenotypes, making them amenable to investigation of early pathophysiological, and later parkinsonian-like, alterations. This model will prove valuable in efforts to develop neuroprotection for PD.
Amyloid-Beta-Related Angiitis with Distinctive Neuro-Ophthalmologic Features
Dumitrașcu, Oana , Okazaki, Erin, Cobb, Steven H., Zarka, Matthew A., Souza, Stephen De , Kumar, Gyanendra , O’Carroll, Cumara B. , Dumitrascu, Oana M , Okazaki, Erin M

Mayo Clinic

Neuro-Ophthalmology | September 19, 2017 | Volume: 42 | Issue: 4 | Pages: 237-241

10.1080/01658107.2017.1374982 | PMID 30042795 Get It

St. Louis encephalitis virus possibly transmitted through blood transfusion—Arizona, 2015
Venkat, Heather , Adams, Laura E. , Sunenshine, Rebecca, Krow‐Lucal, Elisabeth , Levy, Craig, Kafenbaum, Tammy, Sylvester, Tammy, Smith, Kirk, Townsend, John, Dosmann, Melissa, Kamel, Hany , Patron, Roberto L. , Kuehnert, Matthew J. , Annambhotla, Pallavi , Basavaraju, Sridhar V. , Rabe, Ingrid B., Team, SLEV Transmission Investigation, Patron, Roberto, Townsend, John, Team, SLEV Transmission Investigation

Mayo Clinic

Transfusion | September 14, 2017 | Volume: 57 | Issue: 12 | Pages: 2987-2994

10.1111/trf.14314 | PMID 28905395 Get It

BACKGROUNDSt. Louis encephalitis virus is a mosquito‐borne flavivirus that infrequently causes epidemic central nervous system infections. In the United States, blood donors are not screened for St. Louis encephalitis virus infection, and transmission through blood transfusion has not been reported. During September 2015, St. Louis encephalitis virus infection was confirmed in an Arizona kidney transplant recipient. An investigation was initiated to determine the infection source.STUDY DESIGN AND METHODSThe patient was interviewed, and medical records were reviewed. To determine the likelihood of mosquito‐borne infection, mosquito surveillance data collected at patient and blood donor residences in timeframes consistent with their possible exposure periods were reviewed. To investigate other routes of exposure, organ and blood donor and recipient specimens were obtained and tested for evidence of St. Louis encephalitis virus infection.RESULTSThe patient presented with symptoms of central nervous system infection. Recent St. Louis encephalitis virus infection was serologically confirmed. The organ donor and three other organ recipients showed no laboratory or clinical evidence of St. Louis encephalitis virus infection. Among four donors of blood products received by the patient via transfusion, one donor had a serologically confirmed, recent St. Louis encephalitis virus infection. Exposure to an infected mosquito was unlikely based on the patient's minimal outdoor exposure. In addition, no St. Louis encephalitis virus‐infected mosquito pools were identified around the patient's residence.CONCLUSIONThis investigation provides evidence of the first reported possible case of St. Louis encephalitis virus transmission through blood product transfusion. Health care providers and public health professionals should maintain heightened awareness for St. Louis encephalitis virus transmission through blood transfusion in settings where outbreaks are identified.
Pemetrexed, Carboplatin, and Concomitant Radiation followed by Surgery for Locally Advanced Esophageal Cancer: Results of a Planned Interim Toxicity Analysis of North Central Cancer Treatment Group Study N044E
Katipamula, Rajini, Jatoi, Aminah , Foster, Nathan R. , Nichols, Francis, Rubin, Joseph, Callister, Matthew D., Gunderson, Leonard L., Nichols, Francis C., Alberts, Steven R.

Mayo Clinic

Clinical medicine. Oncology | September 14, 2017 | Volume: 2 | Issue: No issue available | Pages: No page available

10.4137/cmo.s444 | PMID 21892283 Get It

Purpose This brief report describes a planned, interim, 6-patient toxicity analysis that confirms the safety of pemetrexed, carboplatin, radiation with subsequent surgery, as prescribed in the North Central Cancer Treatment Group trial N044E, in patients with locally advanced esophageal cancer. Methods Six patients with locally advanced, potentially resectable esophageal cancer received pemetrexed 500 mg/m 2 and carboplatin AUC = 6 on days 1 and 22 with 5040 centigray of concomitant radiation in 28 fractions over 5.5 weeks followed by esophagectomy as a prelude to a phase II multi-institutional trial. Results Only 1 of the 6 patients experienced a grade 4 adverse event (neutropenia). This patient also experienced a grade 3 depression. Of the remaining 5 patients, three experienced at least one grade 3 adverse event (neutropenia, nausea/vomiting, and esophagitis). There were no deaths. Incidentally, one patient manifested a complete pathologic response, three a partial pathologic response, and one stable disease. Conclusion These preliminary observations on safety suggest that this regimen can be further studied in this clinical setting.
Tube Thoracostomy Complications: More to Learn: Reply
Zielinski, Martin D. , Aho, Johnathon M. , Hernandez, Matthew C.

Mayo Clinic

World Journal of Surgery | September 11, 2017 | Volume: 42 | Issue: 1 | Pages: 311-312

10.1007/s00268-017-4219-9 | PMID 28884351 Get It

Reply to Letter to the Editor: Paget's Disease of the Temporal Bone: A Single-Institution Contemporary Review of 27 Patients
Deep, Nicholas L. , Besch‐Stokes, Jake , Lane, John I. , Driscoll, Colin L. W., Carlson, Matthew L. , Besch-Stokes, J G

Mayo Clinic

Otology & Neurotology | September 7, 2017 | Volume: 38 | Issue: 10 | Pages: 1547-1548

10.1097/mao.0000000000001562 | PMID 28891874 Get It

Brief Report: A Novel ELANE Mutation Associated With Inflammatory Arthritis, Defective NETosis, and Recurrent Parvovirus Infection
Thanarajasingam, Uma , Jensen, Mark A. , Dorschner, Jessica M., Muskardin, Theresa Wampler , Ghodke‐Puranik, Yogita , Purmalek, Monica , Eliopoulos, Elias , Zervou, Maria I. , Goulielmos, George N. , Howard, Matthew T., Kaplan, Mariana J. , Niewold, Timothy B. , Howard, Matthew

Mayo Clinic

Arthritis & Rheumatology | September 7, 2017 | Volume: 69 | Issue: 12 | Pages: 2396-2401

10.1002/art.40314 | PMID 28881492 Get It

ObjectiveWe describe a 38‐year‐old woman who presented with a history of inflammatory arthritis, rash, and daily fevers. She was noted to have chronic parvovirus infection with persistently detectable viral titers and a novel mutation in the ELANE gene. ELANE encodes neutrophil elastase, a neutrophil serine protease with important antimicrobial effects, and is found as part of neutrophil extracellular trap (NET) complexes. Pathogenic ELANE mutations have been identified in forms of hereditary neutropenia. However, our patient never had neutropenia. Because of the striking clinical scenario, we investigated this mutation functionally.MethodsNET formation by neutrophils was assessed by scanning electron microscopy. Neutrophil activation and neutrophil elastase production were evaluated by flow cytometry and fluorescent substrate–based functional assay, respectively. A multiplex assay was used to quantitate neutrophil inflammatory cytokine production. PyMOL software was used to generate 3‐dimensional models of mutant elastase.ResultsActivated neutrophils from the patient demonstrated a significantly decreased ability to form NETs on scanning electron microscopy, as well as quantitative defects in neutrophil activation and neutrophil elastase activity. The patient's neutrophils showed altered levels of interleukin‐12 (IL‐12) and IL‐8, which are key cytokines for antiviral immunity and neutrophil chemotaxis. Three‐dimensional mapping revealed that the mutation could alter protein folding and surface charge distribution, potentially perturbing protein trafficking. Thus, the mutation could affect neutrophil function by decreasing NETosis and altering key antiviral activities of neutrophils.ConclusionThis is the first report of a human pathogenic ELANE mutation associated with a defect in NETosis and a distinct syndrome of recurrent viral infection and chronic inflammation.
Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers
Javed, Ammar A. , Thoburn, Christopher J. , Wong, Fay , Tie, Jeanne , Allen, Peter J., Schattner, Mark , Petersen, Gloria M. , Hong, Seung‐Mo , Falconi, Massimo , Weiss, Matthew J. , Ahuja, Nita , He, Jin , Makary, Martin A. , Molin, Marco Dal , Li, Lu , Ptak, Janine , Dobbyn, Lisa , Silliman, Natalie , Hruban, Ralph H. , Wolfgang, Christopher L. , Papadopoulos, Nickolas , Kinzler, Kenneth W. , Vogelstein, Bert , Lennon, Anne Marie , Thoburn, Christopher , Javed, Ammar A , Tie, Jeanne , Lennon, Anne Marie , Cohen, Joshua D. , Gibbs, Peter , Schmidt, Christian Max , YIP-SCHNEIDER, Michele T. , Brand, Randall E. , Singhi, Aatur Dilip , Kim, Song Cheol , Doglioni, Claudio , Maitra, Anirban , Hanash, Samir , Wang, Yuxuan , Schaefer, Joy , Popoli, Maria , Goggins, Michael , Klein, Alison P. , Tomasetti, Cristian , Massimo, Falconi

Mayo Clinic

Proceedings of the National Academy of Sciences | September 5, 2017 | Volume: 114 | Issue: 38 | Pages: 10202-10207

10.1073/pnas.1704961114 | PMID 28874546 Get It

Significance Few patients with pancreatic cancer survive longer than 5 y, in part because most patients are identified only after their disease has progressed to an advanced stage. In this study, we show how combining mutations in circulating tumor DNA (ctDNA) with protein markers can result in a screening test with improved sensitivity while retaining specificity. The combination of the ctDNA and protein markers was superior to any single marker. Moreover, the combination detected nearly two-thirds of pancreatic cancers that had no evidence of distant metastasis at the time of surgical resection. The strategy may represent an approach to detect cancers of many types at an earlier stage.
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA -Mutant ER-Positive and HER2-Negative Breast Cancer
Cynthia, X. , Northfelt, Donald W. , Margenthaler, Julie A. , Aft, Rebecca , Gray, Richard J. , Wilke, Lee G. , Haddad, Tufia C. , Moynihan, Timothy J. , Loprinzi, Charles L. , Barnell, Erica K. , Skidmore, Zachary L. , Feng, Yan-Yang, Krysiak, Kilannin , Guo, Zhanfang , Nehring, Leslie, Wisinski, Kari B. , Sanati, Souzan , Al‐Kateb, Hussam , Griffith, Obi L. , Griffith, Malachi , Doyle, L. Austin, Erlichman, Charles , Suman, Vera, Northfelt, Donald, Haddad, Tufia, Moynihan, Timothy, Loprinzi, Charles, Hieken, Tina, Krysiak, Kilannin , Griffith, Malachi , Griffith, Obi L , Suman, Vera J. , Goetz, Matthew P. , Burkard, Mark E. , Ademuyiwa, Foluso O. , Naughton, Michael J. , Tevaarwerk, Amyé , Hieken, Tina J. , Hoog, Jeremy , Mardis, Elaine R. , Hagemann, Ian S. , Vij, Kiran R , Ellis, Matthew J.

Mayo Clinic

Clinical Cancer Research | September 5, 2017 | Volume: 23 | Issue: 22 | Pages: 6823-6832

10.1158/1078-0432.ccr-17-1260 | PMID 28874413 Get It

Abstract Purpose: Hyperactivation of AKT is common and associated with endocrine resistance in estrogen receptor–positive (ER+) breast cancer. The allosteric pan-AKT inhibitor MK-2206 induced apoptosis in PIK3CA-mutant ER+ breast cancer under estrogen-deprived condition in preclinical studies. This neoadjuvant phase II trial was therefore conducted to test the hypothesis that adding MK-2206 to anastrozole induces pathologic complete response (pCR) in PIK3CA mutant ER+ breast cancer. Experimental Design: Potential eligible patients with clinical stage II/III ER+/HER2− breast cancer were preregistered and received anastrozole (goserelin if premenopausal) for 28 days in cycle 0 pending tumor PIK3CA sequencing. Patients positive for PIK3CA mutation in the tumor were eligible to start MK-2206 (150 mg orally weekly, with prophylactic prednisone) on cycle 1 day 2 (C1D2) and to receive a maximum of four 28-day cycles of combination therapy before surgery. Serial biopsies were collected at preregistration, C1D1 and C1D17. Results: Fifty-one patients preregistered and 16 of 22 with PIK3CA-mutant tumors received study drug. Three patients went off study due to C1D17 Ki67 >10% (n = 2) and toxicity (n = 1). Thirteen patients completed neoadjuvant therapy followed by surgery. No pCRs were observed. Rash was common. MK-2206 did not further suppress cell proliferation and did not induce apoptosis on C1D17 biopsies. Although AKT phosphorylation was reduced, PRAS40 phosphorylation at C1D17 after MK-2206 persisted. One patient acquired an ESR1 mutation at surgery. Conclusions: MK-2206 is unlikely to add to the efficacy of anastrozole alone in PIK3CA-mutant ER+ breast cancer and should not be studied further in the target patient population. Clin Cancer Res; 23(22); 6823–32. ©2017 AACR.
Molecular targeting of the Aurora-A/SMAD5 oncogenic axis restores chemosensitivity in human breast cancer cells
Gil, Małgorzata , Salisbury, Jeffrey L., Goetz, Mathew P., Haddad, Tufia C. , Iankov, Ianko, Kurokawa, Chenye B., Shumacher, Nicole, D’Assoro, Antonino B. , Suman, Vera, Degnim, Amy, Haddad, Tufia, Ingle, James N. , Galanis, Evanthia , D'Assoro, Antonino B, Opyrchal, Mateusz , Goetz, MP, Suman, Vera J. , Degnim, Amy C. , McCubrey, James Andrew

Mayo Clinic

Oncotarget | September 2, 2017 | Volume: 8 | Issue: 53 | Pages: 91803-91816

10.18632/oncotarget.20610 | PMID 29207686 Get It